Guardant Health, Inc. (NASDAQ:GH) saw a transaction from one of its directors on March 6, 2026, when Manuel Hidalgo Medina sold 1,300 shares of common stock in a sequence of trades that together were worth $118,996. The shares changed hands at prices between $91.3001 and $91.6065.
On the same date, Hidalgo Medina exercised stock options to acquire 1,000 shares of Guardant Health common stock at an exercise price of $32.55 per share, representing a total outlay of $32,549. After settling those moves, his direct holdings in the company stand at 1,193 shares.
The timing of the sale coincides with a period of strong performance for the stock: Guardant Health's share price has climbed roughly 154% over the previous year, though the company’s stock has remained subject to pronounced volatility.
Alongside this insider activity, Guardant Health public disclosures and analyst commentary have drawn attention from market participants.
- Guardant reported fourth-quarter 2025 Shield revenue of $35.1 million, an outcome that matched the company’s earlier preannouncement.
- Following the preliminary Q4 results, Canaccord Genuity raised its price target on Guardant Health to $135 and reiterated a Buy rating after the quarter exceeded both the firm’s estimates and the FactSet consensus.
- Stifel increased its price target to $130 and maintained a Buy rating, referencing Guardant’s 2026 guidance that emphasizes commercial expansion alongside cost discipline.
- Baird initiated coverage with an Outperform rating and set a $120 price target, assigning a Speculative Risk designation to the stock.
- Academic work reported in the Journal of Clinical Oncology found that Guardant’s circulating tumor DNA (ctDNA) blood test more accurately predicts colon cancer recurrence than traditional methods.
Separately, InvestingPro analysis referenced in company coverage indicates that Guardant Health currently appears overvalued when measured against its Fair Value assessment. InvestingPro also offers a Pro Research Report covering GH and more than 1,400 other U.S. equities for readers seeking deeper analysis.
The combination of insider transactions, fresh revenue data from Shield, multiple analyst target adjustments, and academic validation of the company’s ctDNA test frames a complex picture: notable commercial traction and research progress coexist with elevated market valuations and share-price volatility. The director’s sale and simultaneous option exercise are discrete, documented moves; they do not, on their own, resolve questions about valuation or near-term stock direction.
Investors and market observers should note the specific facts: the 1,300-share sale on March 6, 2026, at prices between $91.3001 and $91.6065 for a total of $118,996; the 1,000-option exercise at $32.55 per share totaling $32,549; a post-transaction direct ownership of 1,193 shares by Manuel Hidalgo Medina; Q4 2025 Shield revenue of $35.1 million that matched the company preannouncement; and multiple analyst actions including Canaccord Genuity's $135 target, Stifel’s $130 target, and Baird’s $120 target with an Outperform start and Speculative Risk tag.
These items together underpin current market narratives around Guardant Health, but they remain factual observations rather than predictive signals.